Statin use vs. average non-HDL cholesterol levels in Trinidad and Tobago
Trinidad and Tobago: Statin use vs. average non-HDL cholesterol levels was 3.5 in 2018. ▬ Flat
Statin use vs. average non-HDL cholesterol levels in Trinidad and Tobago, 1980–2018
Source: World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.
Analysis
The most recent figure for statin use vs. average non-hdl cholesterol levels in Trinidad and Tobago is 3.5, measured in 2018. That is the highest value across all 39 years on record.
That represents a change of unchanged over ten years.
Over the whole period, statin use vs. average non-hdl cholesterol levels in Trinidad and Tobago peaked at 3.5 in 1980 and was at its lowest, 3.4, in 1997.
Trinidad and Tobago ranks 52nd of 191 countries on this measure, in the middle of the range.
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1980s | 3.5 | 3.5 | 3.5 | 10 |
| 1990s | 3.47 | 3.4 | 3.5 | 10 |
| 2000s | 3.42 | 3.4 | 3.5 | 10 |
| 2010s | 3.5 | 3.5 | 3.5 | 9 |
Countries ranked near Trinidad and Tobago
- 52 Antigua and Barbuda 3.5 compare
- 52 Bahamas, The 3.5 compare
- 52 Cyprus 3.5 compare
- 52 Czechia 3.5 compare
- 52 Dominica 3.5 compare
- 52 El Salvador 3.5 compare
- 52 Finland 3.5 compare
- 52 Greece 3.5 compare
- 52 Grenada 3.5 compare
- 52 Guatemala 3.5 compare
- 52 Haiti 3.5 compare
- 52 Iraq 3.5 compare
- 52 Italy 3.5 compare
- 52 Maldives 3.5 compare
- 52 Micronesia, Fed. Sts. 3.5 compare
- 52 Norway 3.5 compare
- 52 Paraguay 3.5 compare
- 52 Poland 3.5 compare
- 52 St. Kitts and Nevis 3.5 compare
- 52 St. Lucia 3.5 compare
- 52 United Arab Emirates 3.5 compare
- 52 Viet Nam 3.5 compare
More reference data data for Trinidad and Tobago
- Emission Totals - Emissions (N2O) - Manure left on Pasture 0.3189 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 0.0696 (2050)
- Emission Totals - Emissions (CO2eq) from N2O (AR5) - IPCC Agriculture 211.35 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 0.0589 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 0.7976 (2050)
- Emission Totals - Emissions (N2O) - Agricultural Soils 0.7021 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 0.0027 (2050)
- Emission Totals - Emissions (N2O) - Burning - Crop residues 0.001 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 0.2333 (2050)
- Emission Totals - Emissions (CO2eq) from N2O (AR5) - Agricultural Soil 186.05 (2050)
Frequently asked questions
- What is statin use vs. average non-hdl cholesterol levels in Trinidad and Tobago?
- Statin use vs. average non-hdl cholesterol levels in Trinidad and Tobago was 3.5 in 2018, according to World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.
- What is the highest statin use vs. average non-hdl cholesterol levels recorded in Trinidad and Tobago?
- The highest recorded value was 3.5 in 1980.
- What is the lowest statin use vs. average non-hdl cholesterol levels recorded in Trinidad and Tobago?
- The lowest recorded value was 3.4 in 1997.
- How does Trinidad and Tobago rank for statin use vs. average non-hdl cholesterol levels?
- Trinidad and Tobago ranks 52nd out of 191 countries with data for 2018.
- Is statin use vs. average non-hdl cholesterol levels rising or falling in Trinidad and Tobago?
- Over the last ten years it is unchanged. The long-run trend across the full record is flat.
- Where does this Trinidad and Tobago data come from?
- The figures come from World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as part of Statin use vs. average non-HDL cholesterol levels. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 39 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.